| SuperGen, Inc. to Change Name and Stock Ticker Symbol |
 |
 |
 |
 |
 |
/ 0
| Monday, 05 September 2011 00:59 | |||
 SuperGen, Inc. (NASDAQ: SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, announced it anticipates that it will begin operating under the name Astex Pharmaceuticals, Inc. on September 12, 2011.
The new name follows the previously announced closing of its acquisition of Astex Therapeutics Limited, a privately held, UK-based biotechnology company developing targeted therapies. Astex Pharmaceuticals, Inc. is expected to begin trading on NASDAQ under the symbol ASTX on September 12, 2011.
Astex Therapeutics Limited became a wholly owned subsidiary of SuperGen, Inc. on July 20, 2011. Further information about this transaction is available at http://www.astex-supergen.com, or in the investor relations section of the SuperGen website at http://www.supergen.com. About SuperGen SuperGen is a pharmaceutical company dedicated to the discovery and development of novel cancer therapeutics in epigenetic and cell signaling modulation. The Company develops products through biochemical and clinical proof of concept to partner for further development and commercialization. SuperGen developed Dacogen® and receives significant royalties on global sales. For more information about SuperGen, please visit http://www.supergen.com. source:SuperGen, Inc.
|
| Add comment | Add to my library | Forward this article |
eBioDeals of the Day
| No deals for now. |
Share eBioNews:
